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Comment on: External validation of
a prognostic model to predict
survival of patients with sentinel
node-negative melanoma
Editor
Wehave read with great interest the arti-
cle by Ipenburg et al.1. This study exter-
nally validated the developed prognostic
European Organisation for Research
and Treatment of Cancer (EORTC)
model predicting risk of recurrence and
melanoma-specific mortality in patients
with sentinel-node negative melanoma2.
As the models appeared well calibrated
and showed good performance in 4235
patients from the Melanoma Institute
Australia, the authors confirmed the
prognostic accuracy.
We would like to point out some
relevant findings. First, the authors
demonstrated that the EORTC models
were reproducible in an independent
non-European population, thereby
confirming the generalizability. Perfor-
mance in terms of the concordance index
was lower in external validation (0⋅69
for both the recurrence and melanoma-
specific mortality model compared
with 0⋅74 and 0⋅76 in the European
population) but may be explained by dif-
ferences in clinicopathological variables
(e.g. more head and neck melanomas)
and possibly patterns of clinical care.
Second, distribution of patients across
the risk groups was reasonably balanced
(20 per cent low risk, 46 per cent inter-
mediate risk and 34 per cent high risk)
and the Kaplan–Meier plots showed
distinct survival curves, indicating the
clinical usefulness. Third, the possi-
ble additional value of several factors
that could not be sufficiently tested
in the EORTC models was examined,
including mitotic rate and regression.
The latter factor did not show indepen-
dent prognostic value, and the extended
model includingmitotic rate among oth-
ers showed only marginally improved
performance.
In conclusion, the EORTC nomo-
gram is a validated easy-applicable tool
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predicting recurrence and melanoma-
specific mortality in patients with
sentinel-node negative melanoma.
Accurately identifying high-risk patients
could aid in selecting candidates for
adjuvant therapy. To facilitate its use,
an online calculator has been developed
and can be accessed at https://www
.evidencio.com/models/show/1890
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